Novo Partners for Cross BBB Drug Delivery
Novo Nordisk has entered into an R&D collaboration with Ossianix, a Philadelphia-based R&D company. Ossianix utilizes its single domain VNAR antibody to increase drug absorption across the blood brain barrier (BBB). According to the press release, Ossianix will deliver a predefined number of therapeutic agents to Novo for the treatment of diabetes and other metabolic diseases. Below, FENIX provides context of the R&D agreement as well as thoughts on potential targets that Novo is pursuing.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.